AGP Executive Report
Last update: 9 hours agoFederal Access: The DEA has begun registering more than 900 state-licensed medical cannabis dispensaries across several states, potentially opening the door to federal tax relief. Operators still face new compliance requirements. CBD Research: Avecho has restarted recruitment for the final cohort of its pivotal Australian trial of a CBD capsule for insomnia; results are still some way off. Neurotech has begun dosing children in a pivotal trial of a cannabinoid treatment for autism. Hemp Products: Congress’s planned December restrictions could make many hemp-derived products illegal, raising fresh uncertainty for CBD businesses. Elixinol, meanwhile, reports stronger sales and margins for hemp foods. Health Findings: Preliminary research linked cannabis use on just one to five days a month with higher odds of reported stroke, but cannot establish cause. Separate research found little support for medical cannabis as a sleep aid, highlighting the need for stronger clinical trials.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.